Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/05/17
End: 01/09/18
Due: 01/09/19
Phase: N/A
Priority: Normal
Start: 01/03/18
End: 12/01/19
Due: 12/01/20
Phase: N/A
Priority: Normal
Start: 07/31/15
End: 10/31/15
Due: 10/31/16
Phase: N/A
Priority: Normal
Start: 07/31/22
End: 02/28/23
Due: 02/28/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride | NCT03171623 | Yabao Pharmaceutical Group | user2@example.com | None | 2017-04-05 | 2018-01-09 | 2019-01-09 | - | - | 2025-07-14 |
| Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus | NCT03414892 | Yabao Pharmaceutical Group | user2@example.com | None | 2018-01-03 | 2019-12-01 | 2020-12-01 | - | - | 2025-07-14 |
| Bioequivalence Study of Sorafenib Tablet and Nexavar | NCT02599337 | Yabao Pharmaceutical Group | user2@example.com | None | 2015-07-31 | 2015-10-31 | 2016-10-31 | - | - | 2025-07-14 |
| A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, PK and Immunogenicity of YBSW015 in Healthy Subjects | NCT05369754 | Yabao Pharmaceutical Group | user2@example.com | None | 2022-07-31 | 2023-02-28 | 2024-02-28 | - | - | 2025-07-14 |